Compare ATYR & OFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATYR | OFS |
|---|---|---|
| Founded | 2005 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.2M | 54.3M |
| IPO Year | 2015 | 2010 |
| Metric | ATYR | OFS |
|---|---|---|
| Price | $0.18 | $4.01 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $2.86 | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 102.0K |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 17.21% |
| EPS Growth | ★ 6.98 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $190,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.18 | $2.72 |
| 52 Week High | $1.11 | $7.24 |
| Indicator | ATYR | OFS |
|---|---|---|
| Relative Strength Index (RSI) | 18.11 | 55.71 |
| Support Level | N/A | $3.51 |
| Resistance Level | $0.59 | $4.07 |
| Average True Range (ATR) | 0.02 | 0.15 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 8.25 | 64.71 |
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to provide its stockholders with both current income and capital appreciation through debt investments and, to a lesser extent, equity investments.